Q BioMed Inc (OTCQB:QBIO) announced Monday that it has been awarded a contract with UroGPO, the largest group purchasing organization for urology private practice clinics in the US, to make its bone pain treatment Strontium89 available to doctors.
UroGPO members represent 650 urology group practices and 167 ambulatory surgery centers with more than 3,400 urologists. Through the partnership, UroGPO will support the establishment of Strontium89 injections as an added radionuclide therapeutic choice for patients with painful bone metastases from prostate and other urological cancers.
Studies have shown that prostate cancer has the highest risk of bone metastasis, with eight out of 10 metastatic cases spreading to bone, the company said. In the pivotal trial of Strontium89, as many as 79% of patients had pain relief, and twice as many patients treated had no pain for three months than those who received a placebo.
READ: Q BioMed drug receives US Food & Drug Administration orphan drug designation
"Q BioMed is energized by this important partnership,” Q BioMed CEO Denis Corin said in a statement. “We are now better able to access urology practices across the U.S. and meet the needs of prostate cancer patients with painful bone metastases. We are confident that this will enable us to engage with new customers throughout the U.S. and see increased use of Strontium89.”
Strontium89 is administered once every three months via injection, and patients can be re-treated if needed.
"UroGPO member practices continue to show incredible dedication to their prostate cancer patients by increasing access to treatment options,” UroGPO SVP Darren Dieleman said. “We are dedicated to providing the operational support for our members to deliver oral therapies, infused treatments and radiopharmaceuticals in the office site of care. Our leading urologists and their care teams manage patients from diagnosis through advanced disease.”
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel